Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

Autor: Aneta Mikulasova, Cody Ashby, Ruslana G. Tytarenko, Pingping Qu, Adam Rosenthal, Judith A. Dent, Katie R. Ryan, Michael A. Bauer, Christopher P. Wardell, Antje Hoering, Konstantinos Mavrommatis, Matthew Trotter, Shayu Deshpande, Shmuel Yaccoby, Erming Tian, Jonathan Keats, Daniel Auclair, Graham H. Jackson, Faith E. Davies, Anjan Thakurta, Gareth J. Morgan, Brian A. Walker

Publikováno v: Haematologica, Vol 105, Iss 4 (2020)

MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We sho

Externí odkaz: https://doaj.org/article/5a3d144402e64ba28314204a68ef38ea

Supplementary Figure 2: Dinaciclib induces S-phase accumulation and reduces G2/M-phase accumulation from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

Autor: Robert J. Shmookler Reis, Shmuel Yaccoby, Srinivas Ayyadevara, David A. Alagpulinsa

(A, B) H929 cells were treated as indicated for 24 h and cell-cycle distribution assessed by propidium iodide (PI) staining as described in Figure 5.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3f21b9c6ab7127c4bc586f86967c940
https://doi.org/10.1158/1535-7163.22503490

Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Autor: Daniel E.H. Afar, Shmuel Yaccoby, Bart Barlogie, John D. Shaughnessy, Fenghuang Zhan, Audie G. Rice, Debra Chao, Bishwa Ganguly, Balaji Balasa, Rui Yun, Amberly M. Moreno-Bost, JuMei Shi, Tarun K. Garg, Mary K. Stone, Xin Li, Anne M. van Abbema, Myles Dillon, Susann M. Szmania, Frits van Rhee

Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ceb3c738108976650d682599b1dbd3
https://doi.org/10.1158/1535-7163.22486031

Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Autor: Frits van Rhee, Bart Barlogie, Gareth Morgan, Jeffrey Sawyer, John Crowley, Antje Hoering, Clyde Bailey, Susan Panozzo, Douglas Steward, Nathan Petty, Michele Cottler-Fox, Monica Grazziutti, Xenofon Papanikolaou, Rashid Khan, Sarah Waheed, Erming Tian, Shmuel Yaccoby, Maurizio Zangari, Joshua Epstein, Alan Mitchell, Yogesh S. Jethava

Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abnormalities (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c3a8c8f359e69b0b924c1bf0cb619b
https://doi.org/10.1158/1078-0432.22457873.v1

Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers

Autor: Cody Ashby, Brian A Walker, Marco Trevisan-Herraz, Sharmilan Thanendrarajan, Kent Fung, Agata Cieslak, Shmuel Yaccoby, Maurizio Zangari, Aneta Mikulasova, Daniel Rico, Vahid Asnafi, Lisa J. Russell, Nefeli Karataraki, Anne E. Corcoran, Daniel Kent, Sophie Hambleton, Carolina Schinke, Gareth J. Morgan, Salvatore Spicuglia, Frits van Rhee, Chris A. Brackley

Publikováno v: Mikulasova, A, Kent, D, Trevisan-Herraz, M, Karataraki, N, Fung, K T M, Ashby, C, Cieslak, A, Yaccoby, S, van Rhee, F, Zangari, M, Thanendrarajan, S, Schinke, C, Morgan, G J, Asnafi, V, Spicuglia, S, Brackley, C A, Corcoran, A E, Hambleton, S, Walker, B A, Rico, D & Russell, L J 2021, ' Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers ', Genome Research, vol. 2022, 32, pp. 1343-1354 . https://doi.org/10.1101/gr.276042.121

Chromosomal translocations are important drivers of haematological malignancies whereby proto-oncogenes are activated by juxtaposition with enhancers, often called enhancer hijacking. We analysed the epigenomic consequences of rearrangements between

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eedf4484dfbaf56189657b0745b5f853
https://doi.org/10.1101/gr.276042.121